Understanding Revlimid® (lenalidomide)

Revlimid® (lenalidomide) is an immunomodulatory drug that inhibits new blood vessel development on which cancer cells depend for sustenance and growth. Revlimid is the first oral medication that was developed for treatment of myeloma, and it is used in the newly diagnosed and relapsed and/or refractory settings.



Updated April 28, 2021

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.